Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration
{{output}}
Immunotherapy has revolutionized the treatment landscape of advanced non-small-cell lung cancer (NSCLC). However, its efficacy in patients with epidermal growth factor receptor (EGFR)-mutant NSCLC, particularly after failure of EGFR-tyrosine kinase inhibitors ... ...
